Literature DB >> 17402808

Causes and consequences of chronic kidney disease: implications for managed health care.

Daniel E Weiner1.   

Abstract

BACKGROUND: Chronic kidney disease (CKD) is a major public health problem that often goes unrecognized until late-stage disease. In the United States, nearly 20 million people have CKD, and this number is likely to grow as the population ages and the prevalence of diabetes and hypertension rises. With $28 billion currently spent on end-stage renal disease care in the United States and with the rapidly expanding dialysis population, it is essential to actively address this epidemic, both by reducing the number of patients who reach kidney failure and by decreasing morbidity and mortality among those with early-stage CKD.
OBJECTIVE: To review the burden of CKD and its comorbidities on patients, physicians, and payers and discuss the potential benefits to individual patients and society of identifying and treating earlier stages of CKD.
CONCLUSION: Major steps in dealing with the CKD epidemic are (1) identifying individuals at risk for and with earlier stages of CKD, (2) initiating therapies to slow progression of kidney disease, and (3) treating comorbid conditions associated with CKD, including cardiovascular disease and anemia.

Entities:  

Mesh:

Year:  2007        PMID: 17402808     DOI: 10.18553/jmcp.2007.13.s3.1

Source DB:  PubMed          Journal:  J Manag Care Pharm        ISSN: 1083-4087


  14 in total

Review 1.  Obstructive Sleep Apnea and Kidney Disease: A Potential Bidirectional Relationship?

Authors:  Bisher Abuyassin; Kumar Sharma; Najib T Ayas; Ismail Laher
Journal:  J Clin Sleep Med       Date:  2015-08-15       Impact factor: 4.062

2.  Health plan retention and pharmacy costs of newly diagnosed patients with chronic kidney disease in a managed care population.

Authors:  Maureen Kubacki; Chureen Carter; Alan D L Herrera; Jim Wang; Janice M Lopez; Catherine T Piech
Journal:  Am Health Drug Benefits       Date:  2009-11

3.  The PPARβ/δ agonist GW501516 attenuates peritonitis in peritoneal fibrosis via inhibition of TAK1-NFκB pathway in rats.

Authors:  Xuesong Su; Guangyu Zhou; Yanqiu Wang; Xu Yang; Li Li; Rui Yu; Detian Li
Journal:  Inflammation       Date:  2014-06       Impact factor: 4.092

4.  Every-other-week darbepoetin alfa in the correction and maintenance of haemoglobin levels in elderly patients with chronic kidney disease: post hoc subanalysis of data from two clinical trials.

Authors:  Michelle W Krause; Rasib Raja; Anil Agarwal; Marcia R Silver; Debra Scarlata; Angela Sciarra; Reshma Kewalramani
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

5.  Iron-hepcidin dysmetabolism, anemia and renal hypoxia, inflammation and fibrosis in the remnant kidney rat model.

Authors:  Patrícia Garrido; Sandra Ribeiro; João Fernandes; Helena Vala; Elsa Bronze-da-Rocha; Petronila Rocha-Pereira; Luís Belo; Elísio Costa; Alice Santos-Silva; Flávio Reis
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

6.  Salivary Alterations in Rats with Experimental Chronic Kidney Disease.

Authors:  Ana Carolina Romero; Cassia Toledo Bergamaschi; Douglas Nesadal de Souza; Fernando Neves Nogueira
Journal:  PLoS One       Date:  2016-02-09       Impact factor: 3.240

7.  Seroprevalence of Streptococcal Inhibitor of Complement (SIC) suggests association of streptococcal infection with chronic kidney disease.

Authors:  Mohan Ganesh Karmarkar; Gouri Pandharinath Hule; Niwrutti Khandu Hase; Preeti Rajeev Mehta; Scott Robert Walter; Kadaba Srinivasa Sriprakash
Journal:  BMC Nephrol       Date:  2013-05-06       Impact factor: 2.388

8.  Genetic damage in patients with chronic kidney disease, peritoneal dialysis and haemodialysis: a comparative study.

Authors:  Angélica Rangel-López; Maria Eugenia Paniagua-Medina; Marcia Urbán-Reyes; Martha Cortes-Arredondo; Cleto Alvarez-Aguilar; Joel López-Meza; Alejandra Ochoa-Zarzosa; Bengt Lindholm; Elvia García-López; José Ramón Paniagua
Journal:  Mutagenesis       Date:  2013-03       Impact factor: 3.000

9.  Excisional wound healing is delayed in a murine model of chronic kidney disease.

Authors:  Akhil K Seth; Mauricio De la Garza; Robert C Fang; Seok J Hong; Robert D Galiano
Journal:  PLoS One       Date:  2013-03-25       Impact factor: 3.240

10.  Gene therapy by electroporation for the treatment of chronic renal failure in companion animals.

Authors:  Patricia A Brown; Angela M Bodles-Brakhop; Melissa A Pope; Ruxandra Draghia-Akli
Journal:  BMC Biotechnol       Date:  2009-01-16       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.